SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
GSK's headquarters in West London
Lung cancer
GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC
High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light for anti-TIGIT therapies after a string of failures.
September 16, 2024
 · 
2 min read
 · 
Tristan Manalac
Crowd of small symbolic 3d figures linked by lines
ALS
The HEALEY Platform Trial: Quick Failures and New Hope for ALS
Launched in 2020 to more quickly bring to market an effective medicine for amyotrophic lateral sclerosis, the HEALEY Platform Trial has generated disappointing results for many but also continuing programs from Clene and Prilenia.
September 16, 2024
 · 
10 min read
 · 
Heather McKenzie
Messenger RNA or mRNA strand 3D rendering illustration with copy space. Genetics, science, medical research, genome replication concepts.
Vaccines
5 Late-Stage mRNA Vaccines to Watch
The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the market for cancer, influenza and more.
September 16, 2024
 · 
5 min read
 · 
Ben Hargreaves
A scientist with pill bottles in front of FDA headquarters
FDA
FDA Action Alert: BMS, Merck, Sanofi/Regeneron and More
The FDA has six target action dates ahead to round out September as drugs for gastroparesis, Niemann-Pick disease type C and more await decisions.
September 16, 2024
 · 
6 min read
 · 
Tristan Manalac
Dragon and eagle with money
Editorial
BIOSECURE Act Targets China but Fails to Address Fallout for US Biopharma
It’s time for Congress to step up and fund America’s supply chain independence from Chinese companies by bolstering our domestic manufacturing capabilities.
September 13, 2024
 · 
4 min read
 · 
Greg Slabodkin
Giant robot flicking tiny man. Ai technologies and unemployment problem concept. Vector illustration.
Layoffs
Oncternal to Lay Off 37% of Employees, Including CMO
Oncternal Therapeutics will lay off about 10 workers as it explores “strategic alternatives” that could include asset sales or an M&A.
September 13, 2024
 · 
1 min read
 · 
Angela Gabriel
This illustration is a JPG File to depict Entrepreneurship skills
Drug Development
Facing ‘Daunting’ Launch Schedule, Moderna to Slash $4B in R&D Spend by 2028
Analysts expressed skepticism about plans detailed by Moderna’s R&D chief Stephen Hoge to trim research spending in preparation for the launch of up to 10 new products.
September 13, 2024
 · 
4 min read
 · 
Annalee Armstrong
Wall Street sign with a background of skyscrapers in Lower Manhattan, New York City
IPO
3 Biotechs Seek Over $700M in Renewed IPO Rush
Bicara Therapeutics, Zenas BioPharma and MBX Biosciences are seeking a combined $700 million-plus in IPO filings this week.
September 13, 2024
 · 
2 min read
 · 
Annalee Armstrong
Pictured: Roche tower in Basel, Switzerland
Approvals
Roche Gains PD-1 Edge on Merck With FDA Nod for Subcutaneous Tecentriq
Tecentriq Hybreza, which combines Roche’s Tecentriq with Halozyme Therapeutics’ Enhanze drug delivery technology, is being touted as the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy.
September 13, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS